Sigilon Therapeutics

Sigilon Therapeutics is pioneering a new therapeutic technology and seeking to develop functional therapies for patients with various chronic diseases. Sigilon Therapeutics' Shielded Living Therapeutics™ platform combines advanced cell engineering with innovations in biocompatible materials, potentially enabling our product candidates to produce a variety of therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies, and enzymes.Sigilon Therapeutics' platform technology is inspired by over a decade of work from MIT academic co-founders Bob Langer and Dan Anderson and supported by Flagship Pioneering’s strategic vision. This work collectively paves the way for us to build a diversified pipeline spanning rare blood disorders, lysosomal storage diseases, and endocrine disorders.